AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10678926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine (4.5 x 10(8) CFU)
Number of subjects: 80
Study 10678926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose vaccine (5 x 10(7) CFU)
Number of subjects: 80
Study 10678926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and lower-dose vaccines
Number of subjects: 80
Study 10678926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9685538 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 91
Study 9685538 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 91
Study 8290185 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute incremental oxytocin infusion regimen
Number of subjects: 124
Study 8290185 — intervention group
Group type: COMPARATOR
Intervention: 15-minute incremental oxytocin infusion regimen
Number of subjects: 124
Study 2566779 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 4 months
Number of subjects: 22
Study 1097222 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of prednisone
Number of subjects: 19
Study 1097222 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance administration of prednisone
Number of subjects: 19
Study 1097222 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prednisone when headaches began
Number of subjects: 19
Study 1097222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31888738 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 31888738 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 28704410 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation manipulation
Number of subjects: 0
Study 28704410 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25176389 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 202
Study 25176389 — intervention group
Group type: COMPARATOR
Intervention: Control (Cyclosporine)
Number of subjects: 202
Study 23386556 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA) training
Number of subjects: 24
Study 21492377 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion method group (32 patients) with 300-500 mL warm normal saline infused into the bladder before IDC removal
Number of subjects: 60
Study 21492377 — intervention group
Group type: COMPARATOR
Intervention: Standard IDC removal group (28 patients)
Number of subjects: 60
Study 17876505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50
Study 17876505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with multimodal behavior therapy
Number of subjects: 50
Study 17876505 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 16426470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1)
Number of subjects: 120
Study 16426470 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg kg(‐1)
Number of subjects: 120
Study 16426470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 120
Study 16426470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120
Study 16426470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Meperidine
Number of subjects: 120
Study 14557583 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (400 mg/day)
Number of subjects: 1
Study 14557583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 10848743 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% solution nail lacquer + oral terbinafine for 6 weeks (AT6 group)
Number of subjects: 147
Study 10848743 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% solution nail lacquer + oral terbinafine for 12 weeks (AT12 group)
Number of subjects: 147
Study 10848743 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine alone for 12 weeks (Control group)
Number of subjects: 147
Study 9116614 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral stem cell transplantation (PSCT)
Number of subjects: 116
Study 9116614 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 116
Study 9116614 — intervention group
Group type: EXPERIMENTAL
Intervention: PSCT
Number of subjects: 116
Study 7907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg, given twice weekly for 6 weeks
Number of subjects: 24
Study 7907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 3, 10, or 30 mg/kg
Number of subjects: 24
Study 7907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg
Number of subjects: 24
Study 7907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine)
Number of subjects: 24
Study 2640452 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (0.5 mg/kg body weight)
Number of subjects: 5
Study 2640452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31092460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 73
Study 31092460 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 73
Study 28499258 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of positive alcohol expectancies
Number of subjects: 870
Study 28499258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline levels of positive alcohol expectancies (US sample)
Number of subjects: 870
Study 28499258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline levels of drinks per week (US sample)
Number of subjects: 870
Study 28499258 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in positive alcohol expectancies over time (Swedish sample)
Number of subjects: 870
Study 25668333 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive sedimentation sign
Number of subjects: 115
Study 24045669 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68 plus S-1/CDDP
Number of subjects: 93
Study 24045669 — intervention group
Group type: COMPARATOR
Intervention: S-1/CDDP
Number of subjects: 93
Study 21456072 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen blockade (TAB)
Number of subjects: 131
Study 21456072 — intervention group
Group type: COMPARATOR
Intervention: Polyestradiol phosphate (PEP)
Number of subjects: 131
Study 18155050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 5 mg per mL
Number of subjects: 40
Study 18155050 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal ropivacaine 10 mg per mL
Number of subjects: 40
Study 18155050 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bupivacaine and ropivacaine
Number of subjects: 40
Study 17184102 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified conjugated estrogens (ECE) 0.156 mg/day (ultra low‐dose) (n = 18)
Number of subjects: 35
Study 17184102 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified conjugated estrogens (ECE) 0.312 mg/day (low‐dose) (n = 17)
Number of subjects: 35
Study 12900696 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseball velocity of 26.8 m.s(‐1)
Number of subjects: 100
Study 12900696 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseball velocity of 33.5 m.s(‐1)
Number of subjects: 100
Study 12900696 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention conditions (full attention and attention splitting)
Number of subjects: 100
Study 10691814 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemi-KUB X-rays
Number of subjects: 2
Study 10691814 — intervention group
Group type: COMPARATOR
Intervention: Standard radiological procedures (control group)
Number of subjects: 2
Study 9093637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg DEC
Number of subjects: 31
Study 9093637 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg DEC
Number of subjects: 31
Study 9093637 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg DEC
Number of subjects: 31
Study 9093637 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (various doses)
Number of subjects: 31
Study 1552649 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping smoking (Group A)
Number of subjects: 90
Study 1552649 — intervention group
Group type: COMPARATOR
Intervention: Continuing smoking (Group B)
Number of subjects: 90
Study 2866071 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sulfasalazine
Number of subjects: 28
Study 2866071 — intervention group
Group type: COMPARATOR
Intervention: On-demand sulfasalazine
Number of subjects: 28
Study 2866071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal biopsies
Number of subjects: 28
Study 29280763 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg diazepam capsules
Number of subjects: 49
Study 29280763 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 49
Study 29462827 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniportal VATS
Number of subjects: 135
Study 29462827 — intervention group
Group type: COMPARATOR
Intervention: Two-port VATS
Number of subjects: 135
Study 29462827 — intervention group
Group type: COMPARATOR
Intervention: Three-port VATS
Number of subjects: 135
Study 29462827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence rate
Number of subjects: 135
Study 29462827 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of drainage
Number of subjects: 135
Study 27321474 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral progesterone daily
Number of subjects: 591
Study 27321474 — intervention group
Group type: COMPARATOR
Intervention: No progesterone support
Number of subjects: 591
Study 23348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 62
Study 23348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 62
Study 23348061 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 62
Study 23348061 — intervention group
Group type: COMPARATOR
Intervention: Motivation (autonomous vs controlled)
Number of subjects: 62
Study 22133703 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 50
Study 22133703 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 50
Study 22133703 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVH
Number of subjects: 50
Study 22133703 — intervention group
Group type: COMPARATOR
Intervention: TAH
Number of subjects: 50
Study 20018535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone (60 mg)
Number of subjects: 21
Study 20018535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic STEMI protocol during regular hours (n=258)
Number of subjects: 597
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic STEMI protocol during off hours (n=258)
Number of subjects: 597
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic STEMI protocol during regular hours (n=105)
Number of subjects: 597
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic STEMI protocol during off hours (n=105)
Number of subjects: 597
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy during regular hours (n=131)
Number of subjects: 597
Study 19393151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy during off hours (n=131)
Number of subjects: 597
Study 16157799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 consecutive, abnormal, reliable VF test results
Number of subjects: 68
Study 16157799 — intervention group
Group type: COMPARATOR
Intervention: 3 consecutive, abnormal, reliable VF test results
Number of subjects: 68
Study 12014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community (TC) treatment
Number of subjects: 275
Study 10064293 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment and recording programme implemented in the study group
Number of subjects: 0
Study 10064293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing interventions in the study group
Number of subjects: 0
Study 10064293 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording of falls in the study group
Number of subjects: 0
Study 10064293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no risk assessment or preventive interventions)
Number of subjects: 0
Study 10064293 — intervention group
Group type: COMPARATOR
Intervention: Injuries related to falls in the control group
Number of subjects: 0
Study 9454190 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 blood type in patients with glottis cancer
Number of subjects: 500
Study 9454190 — intervention group
Group type: EXPERIMENTAL
Intervention: A1B blood type in patients with hypopharynx cancer
Number of subjects: 500
Study 2268489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole with albumin added to the peritoneal cavity (250‐500 mg/100 ml)
Number of subjects: 0
Study 2268489 — intervention group
Group type: COMPARATOR
Intervention: Control (without albumin)
Number of subjects: 0
Study 2268489 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin added to dialysate
Number of subjects: 0
Study 7092633 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%, one drop every 12 hours
Number of subjects: 0
Study 7092633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg, every 12 hours
Number of subjects: 0
Study 7092633 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol maleate added to oral acetazolamide
Number of subjects: 0
Study 7092633 — intervention group
Group type: COMPARATOR
Intervention: Oral acetazolamide added to topical timolol
Number of subjects: 0
Study 31646623 — intervention group
Group type: EXPERIMENTAL
Intervention: Free nicotine patches
Number of subjects: 600
Study 31646623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicotine patches)
Number of subjects: 600
Study 31646623 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months after quitting
Number of subjects: 600
Study 31800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Child protection system involvement
Number of subjects: 46
Study 31800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 46
Study 31800634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural factors interaction with family violence
Number of subjects: 46
Study 29081151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (4 ml/kg) with general anesthesia (Group H1)
Number of subjects: 120
Study 29081151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (4 ml/kg) with spinal canal anesthesia (Group H2)
Number of subjects: 120
Study 29081151 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (4 ml/kg) with general anesthesia (Group C1)
Number of subjects: 120
Study 29081151 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (4 ml/kg) with spinal canal anesthesia (Group C2)
Number of subjects: 120
Study 25505035 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml 0.5% bupivacaine plus 0.5 ml (20 mg) methylprednisolone
Number of subjects: 69
Study 25505035 — intervention group
Group type: COMPARATOR
Intervention: 2.75 ml normal saline plus 0.25 ml 1% lidocaine without epinephrine (placebo)
Number of subjects: 69
Study 23790912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol 6.0g
Number of subjects: 30
Study 23790912 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent in energy and carbohydrates
Number of subjects: 30
Study 22855579 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668
Study 22855579 — intervention group
Group type: COMPARATOR
Intervention: No Thalidomide
Number of subjects: 668
Study 22855579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NR3C1 levels at relapse
Number of subjects: 668
Study 18936867 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroplastique(R) Implantation System (MPQ)
Number of subjects: 45
Study 18936867 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises home program
Number of subjects: 45
Study 17261567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 180
Study 17261567 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT) autograft
Number of subjects: 180
Study 14973800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat (0.08 mg/kg)
Number of subjects: 40
Study 14973800 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isotonic saline solution
Number of subjects: 40
Study 12575546 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Granule (QGG)
Number of subjects: 66
Study 12575546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Granule (BSG)
Number of subjects: 66
Study 12575546 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 66
Study 9042869 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition enriched with omega-3 fatty acids
Number of subjects: 40
Study 9042869 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control nutrition
Number of subjects: 40
Study 8037492 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT therapy with ADM, CPA, and tamoxifen
Number of subjects: 0
Study 8037492 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of chemotherapy
Number of subjects: 0
Study 8037492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy with G‐CSF or bone marrow transplantation
Number of subjects: 0
Study 8037492 — intervention group
Group type: EXPERIMENTAL
Intervention: New promising drugs for chemotherapy such as taxanes
Number of subjects: 0
Study 3340910 — intervention group
Group type: EXPERIMENTAL
Intervention: Early umbilical cord clamping
Number of subjects: 38
Study 3340910 — intervention group
Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (1 minute)
Number of subjects: 38
Study 29668720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical periodontal therapy plus adjunctive antibiotics (amoxicillin 500 mg and metronidazole 400 mg, 3x/day for 7 days)
Number of subjects: 89
Study 29668720 — intervention group
Group type: COMPARATOR
Intervention: Mechanical periodontal therapy only
Number of subjects: 89
Study 26500139 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN alone, 10 mg per day, 21 days per 4 weeks (L arm)
Number of subjects: 131
Study 26500139 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN (same schedule) + erythropoietin (EPO) beta, 60,000 U per week (LE arm)
Number of subjects: 131
Study 25481046 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels assessed prior to cardioversion
Number of subjects: 199
Study 23609382 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 40
Study 23609382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19839945 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated side
Number of subjects: 40
Study 19839945 — intervention group
Group type: COMPARATOR
Intervention: Naïve side
Number of subjects: 40
Study 19301516 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base)
Number of subjects: 77
Study 19301516 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 77
Study 16880101 — intervention group
Group type: EXPERIMENTAL
Intervention: PVCAP determined by Doppler echocardiography
Number of subjects: 54
Study 12644421 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-tetanic count (PTC) in diabetic patients
Number of subjects: 36
Study 12644421 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) in diabetic patients
Number of subjects: 36
Study 12644421 — intervention group
Group type: COMPARATOR
Intervention: Onset of neuromuscular block after vecuronium (0.1 mg kg(‐1)) in diabetic patients
Number of subjects: 36
Study 10665616 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 74
Study 10665616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9274547 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/day of elemental calcium)
Number of subjects: 591
Study 9274547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 8436148 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d (increased to 40 mg/d if necessary)
Number of subjects: 45
Study 8436148 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg/d (increased to 100 mg/d if necessary)
Number of subjects: 45
Study 3523346 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of immunoglobulins
Number of subjects: 20
Study 3523346 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 20
Study 31916979 — intervention group
Group type: EXPERIMENTAL
Intervention: CP plus four immunizations with oregovomab (CPO)
Number of subjects: 97
Study 31916979 — intervention group
Group type: COMPARATOR
Intervention: Standard six cycle IV carboplatin‐paclitaxel chemotherapy (CP)
Number of subjects: 97
Study 29575254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and nedaplatin (80 mg/m2) administered every 28 days for 5 cycles after radical hysterectomy
Number of subjects: 62
Study 27404673 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan treatment for 2 days
Number of subjects: 217
Study 27404673 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 217
Study 24241487 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 497